Spanish Validation Frustration Discomfort Scale

June 17, 2020 updated by: Universitat Jaume I

Spanish Validation of the Frustration Discomfort Scale

This is an observational study aimed at validating the Frustration Discomfort Scale (Harrington, 2005). A back-translation process was followed to obtain a translated version of the scale, which was refined after a discussion with several clinicians.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

In the study, the Spanish adaptation of the Frustration Discomfort Scale will be disseminated with an online questionnaire using the Qualtrics platform. Additional questionnaires to explore the validity of the adapted scale will also be administered. Participants who complete the questionnaires and provide a valid ID number will enter a participate in a raffle to win an Amazon coupon of 40 euros. Ten coupons will be offered in total amongst participants.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1513

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Castellón De La Plana, Spain
        • Faculty of Psycholoy. Jaume I University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

This protocol will be disseminated globally to the population in Spain with no restriction. The maximum efforts will be made to disseminate the study to a wide range of individuals

Description

Inclusion Criteria:

  • Being over 18 years of age
  • Signs the informed consent
  • Can read and understand Spanish
  • Has access to a computer, a tablet or a smartphone with an internet connection

Exclusion Criteria:

  • Being younger than 18 years of age
  • Does not sign the informed consent
  • Cannot read or understand Spanish
  • Does not have access to a computer, a tablet or a smartphone with an internet connection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Frustration Discomfort Scale
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This is a measure of frustration intolerance. The original English version has been translated using a back-translation method and discussions about item have been made with clinicians with expertise in the field. The scale has 28 items that are gouped in 4 subscales. Items have a 1-to-5 response scale ranging from "nothing" to "a lot"
The measure will be administered 1 day once only together with the remaining measures

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Rosenberg self-esteem scale
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This scale of self-esteem has 10 items with responses ranging from 1 (completely agree) to 4 (completely disagree). This measure will be used for concurrent criterion validity analyses
The measure will be administered 1 day once only together with the remaining measures
Satisfaction with life scale
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This 5-item scale measures an individual's satisfaction with life using response options ranging from 1 (completely disagree) to 5 (completely agree). This measure will be used for concurrent criterion validity analyses
The measure will be administered 1 day once only together with the remaining measures
Acceptance and action questionnaire - II
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This 7-item scale measures acceptance of difficult experiences using a 7-point response scale (1= never true; 7=always true). This measure will be used for construct validity analyses
The measure will be administered 1 day once only together with the remaining measures
STAXI - 2 (trait anger scale only)
Time Frame: The measure will be administered 1 day once only together with the remaining measures
The trait anger scale of the STAXI-2, which has 10 items, will be used to evaluate trait anger. The responses in the scale range from 1="not at all" to 4="very much". This measure will be used for concurrent criterion validity analyses
The measure will be administered 1 day once only together with the remaining measures
Irrational Procrastination Scale
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This 9-item scale will be administered to measure perceived procrastination. Items in the scale have a 5-point range (1=does not describe me at all; 5=decribes me completely). This measure will be used for concurrent criterion validity analyses
The measure will be administered 1 day once only together with the remaining measures
Trait Injustice Experiences Questionnare
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This measure of perceived trait injustice beliefs has 12 items, with responses ranging from 0="never" to 4="always". This measure will be used for construct validity analyses
The measure will be administered 1 day once only together with the remaining measures
European version of the Perceived Stress Scale
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This 10-item measure of perceived stress will be used for concurrent criterion validity analyses. Responses in the scale range from 0="never" to 4="very frequently"
The measure will be administered 1 day once only together with the remaining measures
Patient Health Questionnaire
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This 10-item measure of depressive symptoms will be used for concurrent criterion validity analyses. Response scales range from 0="None of the days" to 3="Almost all days"
The measure will be administered 1 day once only together with the remaining measures
General Anxiety Disorder scale
Time Frame: The measure will be administered 1 day once only together with the remaining measures
This 7-item measure of anxiety symptoms will be used for concurrent criterion validity analyses. Response scales range from 0="None of the days" to 3="Almost all days"
The measure will be administered 1 day once only together with the remaining measures
General Attitudes and Beliefs Scale - reduced
Time Frame: The measure will be administered 1 day once only together with the remaining measures
A shortened, 12-item version of the General Attitudes and Beliefs Scale will be administered. This measure will be used for concurrent criterion validity analyses. Responses in the scale have a 1-5 range (1="completely disagree"; 5="completely agree")
The measure will be administered 1 day once only together with the remaining measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universitat Jaume I

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Universidad de Zaragoza
University of Seville
Universidad Rey Juan Carlos

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 10, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 30, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 30, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 20, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 22, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 23, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 18, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 17, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FrustrationUJI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Only the main PI will have access to the data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings